1stOncology™: Cancer Intelligence Service – Page 11459 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

RGENIX to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

On November 23, 2020 RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, reported that CEO Masoud Tavazoie, M.D., Ph.D., will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference (Press release, Rgenix, NOV 23, 2020, View Source [SID1234571578]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

This virtual presentation will be available online here from November 23, 2020 at 10:00 AM EST to December 3, 2020.

A link to an archived version of this presentation will also be available on RGENIX’s website within the News section.

Rgenix will also be participating in one-on-one meetings with investors on November 30 and December 1, meetings may be requested exclusively via Piper Sandler.

Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference

On November 23, 2020 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing a drug to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, reported that the Company will be participating in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference (Press release, Cardiff Oncology, NOV 23, 2020, View Source [SID1234571577]). Beginning today, November 23rd, a pre-recorded fireside chat with company management will be available for viewing anytime through December 3rd by accessing the recording library on the Piper Sandler conference site.

Cardiff Oncology will also be participating in 1×1 meetings from December 1st – 3rd. Meetings can be requested exclusively via Piper Sandler.

Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies

On November 23, 2020 Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, reported that in 2020, Poseida exercised four options to commercial licenses for Teneobio human heavy chain only domain antibodies, UniDabs, to develop novel CAR T therapies (Press release, TeneoBio, NOV 23, 2020, View Source;utm_medium=rss&utm_campaign=poseida-commercial-license-options-for-unidabs-target-cart-cell-terapies [SID1234571576]). Poseida will apply licensed UniDab binders, which possess significant advantages over traditional single chain variable antibody fragment (scFv) binders, to develop its next generation CAR-T therapies. Targets were not disclosed.

This announcement follows the expansion of a commercial license agreement between the companies that was announced in August of 2018. Under the terms of that agreement, Teneobio would generate multiple UniDab product candidates using its proprietary UniRat transgenic human antibody ‘heavy-chain only’ rodent platform and its state-of-the-art sequence-based discovery engine, TeneoSeek. Poseida would have exclusive global licensing rights for the clinical development and commercialization of specific UniDabs for CAR cell therapies.

Teneobio Inc. receives commercial licensing fees for these milestones and is eligible to receive future research, development and regulatory milestone payments per UniDab candidate, with total potential earnings of over $250 million for CAR-T therapies developed by Poseida. Teneobio would also receive royalties on worldwide net sales of each CAR-T therapy.

"We are excited that Poseida has exercised multiple commercial license options on UniDabs to create the next generation of cell therapies," said Omid Vafa, CBO of Teneobio. "UniDabs have been preclinically and clinically validated as excellent human single domain antibody targeting moieties of CAR T-cells. They have demonstrated both in vivo specificity and robust efficacy. Their advantageous smaller in size, and superior developability relative to standard scFv’s make them ideal for CAR T-cell products."

Eric Ostertag, CEO of Poseida, added, "We have evaluated a large number of binding technologies for use in our CAR-T platforms and view single domain antibodies as one of the most superior. In our view, the fact that Teneobio’s VH binders are fully human makes them a better option than camelid VHH single domain antibodies."

Boston Scientific to Participate in Evercore ISI 2020 Healthcare Conference

On November 23, 2020 Boston Scientific Corporation (NYSE: BSX) reported to participate in the 2020 Evercore ISI HealthCONx Conference on December 1 (Press release, Boston Scientific, NOV 23, 2020, View Source [SID1234571575]).

Mike Mahoney, chairman and chief executive officer, and Susie Lisa, vice president, Investor Relations will participate in a 45-minute question-and-answer session with the host analyst beginning at approximately 8:00 a.m. EST.

A live webcast and replay of the webcast will be accessible at investors.bostonscientific.comView Source The replay will be available beginning approximately one hour following the completion of each event.

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO™ (pralsetinib)

On November 23, 2020 Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, reported that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO (pralsetinib) (Press release, Catalent, NOV 23, 2020, https://www.catalent.com/catalent-news/catalent-signs-commercial-supply-agreement-with-blueprint-medicines-following-fda-approval-of-gavreto-pralsetinib/ [SID1234571574]). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

This agreement will continue Catalent’s involvement in the GAVRETO program, which has been supported by Catalent’s Nottingham, U.K., site since 2015.

GAVRETO is a once-daily oral RET-targeted therapy that is designed to selectively and potently inhibit RET alterations that drive many cancer types, including approximately one to two percent of patients with metastatic NSCLC. Currently, RET is one of seven NSCLC biomarkers that can be targeted with an FDA-approved therapy.

"We have a long-standing relationship with Blueprint Medicines, and this approval marks an amazing accomplishment, reflecting the hard work, dedication and determination of the entire team," commented Jonathan Arnold, President of Oral and Specialty Delivery at Catalent. "The expertise that our scientists in Nottingham brought to the development program supported Blueprint Medicines’ efforts to rapidly gain regulatory approval, and through expedient tech transfer within our company’s global network, our team in Kansas City can effectively support commercial supply."

In February 2020, Catalent announced a commercial supply agreement for Blueprint Medicines’ AYVAKIT (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

Catalent’s Kansas City, Missouri site is home to the company’s Oral & Specialty Drug Delivery business, where it provides a range of integrated services for oral solid dosage forms, from formulation development and analytical testing to clinical and commercial-scale manufacture. The 421,665-square-foot facility is the commercial manufacturing Center-of-Excellence for accelerated development programs and roller compaction. It also houses large-molecule analytical services and provides clinical supply services.

Blueprint Medicines, AYVAKIT and GAVRETO are trademarks of Blueprint Medicines Corporation.